08.11.20|Sophie ShulmanCEO Kare Schultz managed over the past three years to keep the boat steady and lessen its debt, but slow growth won’t satisfy investors
19.02.20|Sophie ShulmanTeva’s stock fluctuation is not the result of wrongdoing regarding the U.S. opioid abuse epidemic, but rather something born of the creativity of lawyers, Kåre Schultz said Wednesday at the company’s annual press conference in Tel Aviv
27.11.19|CTechThe Israeli drugmaker is one of six companies to receive subpoenas from federal investigators, the Wall Street Journal reported Tuesday
17.11.19|Sophie ShulmanThe Israeli drugmaker closed 8.74% up on Friday after a Cleveland County District judge reduced the fine placed on Johnson and Jonhson in Oklahoma by $107 million, citing a math error made in the original ruling
23.10.19|Hezi SternlichtThe Israeli drugmaker announced on Monday two major achievements regarding the opioid abuse lawsuits against it; but even without taking into consideration its additional legal complications, the settlements it has reached will severely strain its resources
20.10.19|CTechA $50 billion offer made last week by Teva and the three largest drug distributors in the U.S. does not seem to have panned out, Reuters reported Friday
17.10.19|Hezi SternlichtTeva, a second drugmaker, and the three largest drug distributors in the U.S. have agreed with multiple states on a settlement framework ahead of Monday’s trial, the New York Times reported Thursday
02.10.19|CTechFive of the drugmakers currently battling opioid abuse damages lawsuits in the U.S. are looking to achieve a global settlement through Purdue's bankruptcy case, the Wall Street Journal reported Monday
02.09.19|Hezi SternlichtActavis, which Teva bought from Allergan in 2016 for $40.5 billion, was one of the top U.S. sellers of opioids in 2006-2012
28.08.19|Lilach BaumerTeva, like many other opioid manufacturers operating in the U.S., will be facing multiple opioid abuse-related lawsuits at a trial set to start in October at an Ohio federal court
25.08.19|Hezi SternlichtThe lawsuit seems to be unrelated to the trial set to start against Teva and other opioid manufacturers in October in Ohio federal court
21.08.19|Hezi SternlichtAn opioid-abuse lawsuit settlement reached by drugmakers Endo and Allergan Tuesday could bode well for Teva’s legal future, as does the release of an FDA-approved generic version of EpiPen JR
15.07.19|CTechTeva recently reached an $85 million settlement with the State of Oklahoma regarding its alleged role in the state’s opioid crisis, but is still facing many more claims
27.05.19|Hezi SternlichtTeva is one of several opioid manufacturers being sued in the U.S. by different states and private entities for its alleged role in the nation's opioid addiction crisis
12.05.19|Hezi SternlichtOn Friday, 43 states joined Connecticut in filing a lawsuit against senior Teva executives and against over a dozen former and current senior executives at leading generic drug companies, alleging all were involved in a drug price-fixing conspiracy